The effectiveness and safety of acute venous thromboembolism (VTE) treatment with
rivaroxaban, demonstrated in phase-III trials, needs to be confirmed in daily care. To confirm …

Background: Few studies have identified patterns and predictors of use of direct oral
anticoagulants for venous thromboembolism (VTE). Objective: To describe the use of …

Background Rivaroxaban was reported as effective as traditional therapies for the acute
treatment of venous thromboembolism (VTE) with fewer major bleeding complications in the …

Rivaroxaban for the treatment of venous thromboembolism in r... : Medicine Rivaroxaban for the
treatment of venous thromboembolism in real life: A single-center prospective study : Medicine …

We investigated three-month clinical outcomes in patients with venous thromboembolism
(VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice …

Abstract Background The global EINSTEIN DVT and PE studies compared rivaroxaban (15
mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K …

Background This study aimed to provide safety and efficacy data of rivaroxaban in routine
patient care in a non-selected symptomatic venous thromboembolism (VTE) population …

Two large randomized controlled trials examined the efficacy and safety of rivaroxaban for
the treatment of venous thromboembolism (VTE). The aim of this epidemiological study was …

Introduction Randomized clinical trials have demonstrated non-inferiority of rivaroxaban
compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism …

Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …